Compass Pathways (FRA:5Y6) Debt-to-EBITDA : -0.24 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Compass Pathways's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.19 Mil. Compass Pathways's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €28.00 Mil. Compass Pathways's annualized EBITDA for the quarter that ended in Mar. 2024 was €-124.41 Mil. Compass Pathways's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.24.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Compass Pathways's Debt-to-EBITDA or its related term are showing as below:

FRA:5Y6' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.15 Med: -0.17 Max: -0.02
Current: -0.26

During the past 6 years, the highest Debt-to-EBITDA Ratio of Compass Pathways was -0.02. The lowest was -1.15. And the median was -0.17.

FRA:5Y6's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Healthcare Providers & Services industry
Industry Median: 2.57 vs FRA:5Y6: -0.26

Compass Pathways Debt-to-EBITDA Historical Data

The historical data trend for Compass Pathways's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways Debt-to-EBITDA Chart

Compass Pathways Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-1.15

-0.05

-0.02

-0.29

Compass Pathways Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.02	-0.27	-0.25	-0.27	-0.24

Competitive Comparison of Compass Pathways's Debt-to-EBITDA

For the Medical Care Facilities subindustry, Compass Pathways's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compass Pathways's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Compass Pathways's Debt-to-EBITDA falls into.

Compass Pathways Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Compass Pathways's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.211	+	28.096)	/	-105.673
	=	-0.29

Compass Pathways's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.19	+	27.995)	/	-124.408
	=	-0.24

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Compass Pathways (FRA:5Y6) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Compass Pathways Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Compass Pathways's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Compass Pathways (FRA:5Y6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (FRA:5Y6) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

CMPS:USA 5Y6:Germany

Address

33 Broadwick Street, London, GBR, W1F 0DQ

Website

https://www.compasspathways.com

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Compass Pathways (FRA:5Y6) Headlines

No Headlines